Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_3
1
33%
Ph not_applicable
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 3Large-scale testing
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)

Detailed Status

Not yet recruiting1
Terminated1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 31 (50.0%)
N/A1 (50.0%)

Trials by Status

not_yet_recruiting133%
terminated133%
completed133%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruiting

Predictors of Thrombus Burden in STEMI Patients and Their Impact on Outcome

NCT06471192
completednot_applicable

PerQseal® Impella Early Feasibility Study

NCT04818541
terminatedphase_3

Bivalirudin Infusion for Ventricular Infarction Limitation

NCT02565147

Clinical Trials (3)

Showing 3 of 3 trials
NCT06471192

Predictors of Thrombus Burden in STEMI Patients and Their Impact on Outcome

Not Yet Recruiting
NCT04818541Not Applicable

PerQseal® Impella Early Feasibility Study

Completed
NCT02565147Phase 3

Bivalirudin Infusion for Ventricular Infarction Limitation

Terminated

All 3 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
3